<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533841</url>
  </required_header>
  <id_info>
    <org_study_id>Ahmed mohamed fathy ismail</org_study_id>
    <nct_id>NCT04533841</nct_id>
  </id_info>
  <brief_title>Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor in Primigravidas</brief_title>
  <official_title>Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor In Primigravidas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed mohamed fathy ismail</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare propranolol and misoprostol versus misoprostol alone for induction of labour in&#xD;
      primigravidas&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Candidates will be randomized into 2 groups according to a computer generated sequence. Each&#xD;
      candidate will be assigned an opaque sealed envelope containing a paper with her group on it.&#xD;
      Both the patient and doctor on duty will be blinded to which group the patient was assigned&#xD;
      to.&#xD;
&#xD;
      - Study procedure:&#xD;
&#xD;
        1. Written informed consent will be obtained from all participants prior to the study.&#xD;
&#xD;
        2. Full history taking.&#xD;
&#xD;
        3. General examination.&#xD;
&#xD;
      Patients will be subjected to the following:&#xD;
&#xD;
        -  Patients attending labour room for induction of labour will be divided into two groups.&#xD;
&#xD;
        -  Both groups, women are induced with Tab misoprostol 25μg applied to posterior vaginal&#xD;
           fornix under aseptic precaution and every 6 hours for a maximum of 4 doses.&#xD;
&#xD;
        -  In group 1, after induction is started with misoprostol placement, 30 minutes will pass&#xD;
           before administration of oral Propanolol 20mg&#xD;
&#xD;
        -  In group 2, after induction is started with misoprostol placement, 30 minutes will pass&#xD;
           before administration of oral placebo in the form of sugary tablets.&#xD;
&#xD;
        -  After induction, women will be monitored for fetal and maternal wellbeing and progress&#xD;
           of labour.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded research</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Induction delivery interval</measure>
    <time_frame>procedure delivery</time_frame>
    <description>The time from starting induction to the delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>delivery</time_frame>
    <description>Vaginal delivery or cesarian section</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Misoprostol + propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient who receive misoprostol then after 30minutes receive propranolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pt who will receive misoprostol then after 30minutes receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol</description>
    <arm_group_label>Misoprostol + placebo</arm_group_label>
    <arm_group_label>Misoprostol + propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Misoprostol + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol</description>
    <arm_group_label>Misoprostol + propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Primigravidas.&#xD;
&#xD;
               -  Full term patients with ultrasound confirmed dates.&#xD;
&#xD;
               -  Singleton.&#xD;
&#xD;
               -  Cephalic presentation.&#xD;
&#xD;
               -  Fetal heart rate between 120 to 160 beats per minute.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Any history of previous surgery on the uterus.&#xD;
&#xD;
               -  Patients in active labour, with ruptured membranes.&#xD;
&#xD;
               -  Fetal distress.&#xD;
&#xD;
               -  Macrosomia or polyhydramnios&#xD;
&#xD;
               -  Hypersensitivity to prostaglandins.&#xD;
&#xD;
               -  Asthmatic patient .&#xD;
&#xD;
               -  liver or kidney impairment .&#xD;
&#xD;
               -  known cardiac patient with abnormal ECG.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female full term pregnancy primigravida</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed S Abd El hamid, A.professor</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem A Hassan elzeneiny, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed mohamed fathy ismail</name>
      <address>
        <city>Zagazig</city>
        <state>El Sharquia</state>
        <zip>055</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed mohamed fathy ismail</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study results will be available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>September 2020</ipd_time_frame>
    <ipd_access_criteria>Researchers</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

